C27 Future directions in ALS genomics

27-11-2019

MNDA SYMPOSIUM PERTH DEC19 PRESENTATIONS

Session 3 Genomics

Naomi Wray - University of Queensland, Brisbane, Australia

Background: Technological advances of the last decade mean that the genome, epigenome, and transcriptome are now more easily measurable. These data, when compared between cases and controls identify disease-associated genes, which help to build a clearer picture of ALS biology.

Whereas the genome is the same in every cell and throughout life, the other ‘omics measures can reflect biological responses to the environment and the disease process. Differences in ‘omics measures between cases and controls can generate hypotheses about disease process, and differences amongst cases may help understanding of disease progression and between individual-heterogeneity. One limitation of this approach is that causes and consequences of disease may be confounded.

Another approach is to integrate genomic data from ALS cases/controls with ‘omics data generated on healthy people. Integration is via DNA polymorphisms. For example, if a DNA polymorphism is associated with ALS, we can interrogate reference data sets to ask if the variant controls variation between people in DNA methylation or gene expression, and if so, is this control of gene expression tissue-specific. In this way, bioinformatics analyses can quickly and cheaply generate hypotheses for testing in a laboratory.

The rapid changes in technology mean that this is a fast-moving field; the future potential for knowledge advancement is even greater. For example, reference data sets that identify DNA polymorphism that impact variation in specific cell types are still accumulating.

Drawing on examples from our in-house genome, epigenome and transcriptome data in ALS and other disorders, we will conclude that these technologies hold great promise for furthering our understanding of ALS. Given the great clinical heterogeneity between those diagnosed with ALS and given the millions of measures created by the technologies, large sample cohorts are needed to generate valid and replicated results. Hence, contributing to research through providing both clinical measures and biological samples is a very important legacy for those with ALS today. It is with the vision of what current and future ‘omics technologies can deliver that we established the SALSA Systems Genomics Consortium, funded by the Ice Bucket Challenge in Australia.

Source: Abstract Book symposium Perth